Stephens Inc. AR decreased its holdings in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 27.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,988 shares of the medical equipment provider’s stock after selling 5,279 shares during the quarter. Stephens Inc. AR’s holdings in GenMark Diagnostics were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of GNMK. Campbell & CO Investment Adviser LLC acquired a new position in GenMark Diagnostics in the 4th quarter worth $84,000. Virtu Financial LLC bought a new stake in shares of GenMark Diagnostics in the 3rd quarter worth about $179,000. Engineers Gate Manager LP bought a new stake in shares of GenMark Diagnostics in the 3rd quarter worth about $213,000. OLD National Bancorp IN increased its position in shares of GenMark Diagnostics by 5.9% in the 4th quarter. OLD National Bancorp IN now owns 48,475 shares of the medical equipment provider’s stock worth $236,000 after purchasing an additional 2,700 shares during the last quarter. Finally, MetLife Investment Advisors LLC increased its position in shares of GenMark Diagnostics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 40,896 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 14,546 shares during the last quarter. Institutional investors and hedge funds own 95.09% of the company’s stock.
In other GenMark Diagnostics news, SVP Michael Gleeson sold 26,704 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $7.96, for a total value of $212,563.84. Following the completion of the transaction, the senior vice president now owns 401,565 shares in the company, valued at approximately $3,196,457.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Hany Massarany sold 15,166 shares of the company’s stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $5.90, for a total transaction of $89,479.40. Following the completion of the transaction, the insider now owns 692,062 shares of the company’s stock, valued at approximately $4,083,165.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 143,936 shares of company stock valued at $980,532. 7.09% of the stock is owned by insiders.
GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Thursday, February 21st. The medical equipment provider reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). GenMark Diagnostics had a negative return on equity of 107.77% and a negative net margin of 71.37%. The firm had revenue of $19.38 million during the quarter, compared to the consensus estimate of $19.22 million. As a group, research analysts forecast that GenMark Diagnostics, Inc will post -0.74 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on GNMK shares. ValuEngine raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. BidaskClub raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, January 7th. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, November 19th. Raymond James set a $7.00 target price on shares of GenMark Diagnostics and gave the stock a “buy” rating in a research report on Thursday, December 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of GenMark Diagnostics in a research report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $9.75.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Featured Story: How does inflation affect different investments?
Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc (NASDAQ:GNMK).
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.